SCHEMBL22127489

SCHEMBL22127489

C=CC[C@@]1(CNC(=O)OC(C)(C)C)C(=O)N(C(=O)c2ccccc2)CCN1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPC1L1 Q9UHC9 9/20 0.36
NPFFR1 Q9GZQ6 1/20 0.35
NPFFR2 Q9Y5X5 1/20 0.35
KDM4E B2RXH2 1/20 0.34
PKM P14618 1/20 0.34
SIGMAR1 Q99720 2/20 0.34
ALDH1A1 P00352 1/20 0.34
AVPR2 P30518 1/20 0.34
DRD2 P14416 1/20 0.33
IDO1 P14902 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22127490 1.00 NPC1L1 (0.36) NPC1L1NPFFR1NPFFR2KDM4EPKM
SCHEMBL29607523 0.94 KDM4E (0.38) NPC1L1NPFFR1NPFFR2KDM4EPKM
SCHEMBL22127476 0.83 NPC1L1 (0.37) NPC1L1NPFFR1NPFFR2KDM4EPKM
SCHEMBL22127477 0.83 NPC1L1 (0.37) NPC1L1NPFFR1NPFFR2KDM4EPKM
SCHEMBL17858904 0.81 NPC1L1 (0.38) NPC1L1NPFFR1NPFFR2KDM4EPKM
SCHEMBL22127523 0.81 LMNA (0.41) ALDH1A1
SCHEMBL22127524 0.81 LMNA (0.41) ALDH1A1
SCHEMBL17858977 0.80 NPFFR1 (0.37) NPC1L1NPFFR1NPFFR2KDM4EPKM
SCHEMBL29607803 0.80 NPC1L1 (0.36) NPC1L1NPFFR1NPFFR2KDM4EPKM
SCHEMBL29608032 0.80 LMNA (0.38) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213081-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME CALIFORNIA INSTITUTE OF TECHNOLOGY 2022-07-07 US disclosed
US-20220119377-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME CALIFORNIA INSTITUTE OF TECHNOLOGY 2022-04-21 US disclosed
US-11214568-B2 Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-01-04 US disclosed
EP-3699173-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME California Institute of Technology (US) 2020-08-26 EP disclosed
US-20200199114-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME CALIFORNIA INSTITUTE OF TECHNOLOGY 2020-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213081-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME GMNN, GRIA1, GRIA2 NPC1L1 3727/4885NPFFR1 3788/4885NPFFR2 3905/4885
US-20200199114-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME GMNN, GRIA1, GRIA2 NPC1L1 3727/4885NPFFR1 3788/4885NPFFR2 3905/4885
US-20220119377-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME GMNN, GRIA1, GRIA2 NPC1L1 3727/4885NPFFR1 3788/4885NPFFR2 3905/4885
US-11214568-B2 Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same GMNN, GRIA1, GRIA2 NPC1L1 3727/4885NPFFR1 3788/4885NPFFR2 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.